Prolonged Treatment With Antithyroid Drugs: How Long to Treat Safely … Months, Years, or a Lifetime?

Peggy Nelson, V. Gossain
{"title":"Prolonged Treatment With Antithyroid Drugs: How Long to Treat Safely … Months, Years, or a Lifetime?","authors":"Peggy Nelson, V. Gossain","doi":"10.1097/TEN.0B013E3181F47FB2","DOIUrl":null,"url":null,"abstract":"Objective: To describe a case where continuous use of antithyroid medications was safely and effectively employed for the treatment of hyperthyroidism over a period of 14 years in a patient who refused radioactive ablative therapy and surgery. Case Report: The patient is a 71-year-old woman who presented with complaints of tachycardia and tremors along with a diffusely enlarged goiter without appreciable nodules. At the time of evaluation, she was clinically and biochemically hyperthyroid. An I123 thyroid uptake and scan revealed a toxic multinodular goiter. She was started on propylthiouracil therapy, which was discontinued due to generalized pruritus. After approximately 4 months of refusing alternative antithyroid therapy, she was started on methimazole. In the subsequent 14 years of management, she relapsed 3 times off antithyroid drugs. However, she never developed any major side effects with the maintenance of methimazole dose of 5 mg daily. Conclusions: The goal of treatment for hyperthyroidism is to render the patient euthyroid safely. However, when treated with radioactive ablative therapy or surgery, the patient is at high risk of being on lifelong thyroxine therapy. Therefore, it appears reasonable that well-informed patients who would prefer lifelong antithyroid therapy, as opposed to lifelong thyroxine therapy, should be given that option.","PeriodicalId":50531,"journal":{"name":"Endocrinologist","volume":"1 1","pages":"217-219"},"PeriodicalIF":0.0000,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinologist","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/TEN.0B013E3181F47FB2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Objective: To describe a case where continuous use of antithyroid medications was safely and effectively employed for the treatment of hyperthyroidism over a period of 14 years in a patient who refused radioactive ablative therapy and surgery. Case Report: The patient is a 71-year-old woman who presented with complaints of tachycardia and tremors along with a diffusely enlarged goiter without appreciable nodules. At the time of evaluation, she was clinically and biochemically hyperthyroid. An I123 thyroid uptake and scan revealed a toxic multinodular goiter. She was started on propylthiouracil therapy, which was discontinued due to generalized pruritus. After approximately 4 months of refusing alternative antithyroid therapy, she was started on methimazole. In the subsequent 14 years of management, she relapsed 3 times off antithyroid drugs. However, she never developed any major side effects with the maintenance of methimazole dose of 5 mg daily. Conclusions: The goal of treatment for hyperthyroidism is to render the patient euthyroid safely. However, when treated with radioactive ablative therapy or surgery, the patient is at high risk of being on lifelong thyroxine therapy. Therefore, it appears reasonable that well-informed patients who would prefer lifelong antithyroid therapy, as opposed to lifelong thyroxine therapy, should be given that option.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
抗甲状腺药物的长期治疗:治疗多长时间是安全的?几个月,几年,还是一生?
目的:描述一个持续使用抗甲状腺药物安全有效地治疗甲状腺机能亢进的病例,该患者拒绝放射性消融治疗和手术治疗14年。病例报告:患者是一名71岁女性,主诉心动过速和震颤,并伴有弥漫性甲状腺肿大,无明显结节。在评估时,她是临床和生化甲状腺功能亢进。I123甲状腺摄取和扫描显示中毒性多结节性甲状腺肿。她开始使用丙硫脲嘧啶治疗,由于全身瘙痒而停止。在拒绝其他抗甲状腺药物治疗约4个月后,她开始服用甲巯咪唑。在随后的14年治疗中,她3次停用抗甲状腺药物复发。但在甲巯咪唑维持每日5mg剂量的情况下,未出现任何重大副作用。结论:甲状腺机能亢进的治疗目标是使患者甲状腺功能安全。然而,当接受放射性消融治疗或手术治疗时,患者终生接受甲状腺素治疗的风险很高。因此,与终生甲状腺素治疗相比,信息灵通的患者更倾向于终生抗甲状腺治疗似乎是合理的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Endocrinologist
Endocrinologist 医学-内分泌学与代谢
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊最新文献
William Osler (1849–1919) Harvey Williams Cushing (1869–1939) Andreas Vesalius (1514–1564) George washington corner 1889–1981 Primary Aldosteronism Complicated by Severe Hypokalemic Myopathy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1